Related Experiment Video
Updated: Jun 18, 2026

06:51
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
28.7K
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
Yonghong Liu1, Jincheng Han1, Wen-Hao Hsu1
1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discovery
|September 30, 2024
Abstract
Significance:
Clinically available KRAS* inhibitors and IO agents alleviated the immunosuppressive tumor microenvironment in PDAC. Profound tumor regression and prolonged survival in an autochthonous PDAC model provide a compelling rationale for combining KRAS* inhibition with IO agents targeting multiple arms of the immunity cycle to combat PDAC.

